The FDA delays by three months (until Jan. 28) a decision on whether to approve AstraZeneca's...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

The FDA delays by three months (until Jan. 28) a decision on whether to approve AstraZeneca's (AZN) and Bristol-Myers Squibb's (BMY) dapagliflozin diabetes pill. In July, an FDA advisory panel voted against approving the medicine, saying more safety information was needed. (PR)